SENTISTM – Hereditary Breast & Ovarian Cancer Panel
BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.
BGI’s Hereditary Breast and Ovarian (HBOC) panel provides health providers with information on 26 genes associated with Hereditary Breast and Ovarian Cancer (HBOC) based on recent scientific and clinical literature. BGI detects different alterations including germline SNV, Indels and CNVs.
Advantages
Panels & Genes
| TEST LIST | GENE LIST |
|---|---|
| Sentis BRCA (2 genes) panel | BRCA1, BRCA2 |
| Sentis Hereditary Breast and Ovarian (26 genes) panel | BRCA1, BRCA2, CHEK2, PALB2, BRIP1, TP53, PTEN, STK11, CDH1, ATM, BARD1, MLH1,NBN, MRE11A,MSH2, MSH6, MUTYH, PMS1,PMS2, RAD50, RAD51C, NF1, EPCAM, SMARCA4, HOXB13 |
SENTISTM Comprehensive Hereditary Cancer Panel
BGI’s hereditary risk screening cancer panels target genes previously linked to a predisposition of cancer. Panel selection was based on expert curation of scientific literature and other high quality resources, including formal medical guidelines.
BGI’s Comprehensive Hereditary Cancer Panel provides information on 79 genes associated with 24 different types of hereditary cancer including some of the most commonly occurring cancers such as hereditary breast, ovarian, colorectal, prostate and stomach cancer. BGI detects different alterations including germline SNV, Indels and CNV.
List of Hereditary Cancers Tested
| HEREDITARY CANCERS | FEMALE PACKAGE | MALE PACKAGE |
|---|---|---|
| Breast | ||
| Ovarian | ||
| Prostate | ||
| Multiple Endocrine Neoplasia | ||
| Thyroid | ||
| Parathyroid | ||
| Neurofibromatosis | ||
| Pheochromocytoma | ||
| Familial Paraganglioma | ||
| Retinoblastoma | ||
| Melanoma | ||
| Chondrosarcoma | ||
| Colorectal | ||
| Pancreatic | ||
| Endometrial | ||
| Gastric | ||
| Renal | ||
| Bladder | ||
| Gastrointestinal Stromal | ||
| Urothelial Carcinoma | ||
| Tuberous Sclerosis | ||
| Nephroblastoma | ||
| Neuroblastoma | ||
| Nevoid Basal Cell Carcinoma |
SENTISTM Lung Cancer Panel
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.
BGI’s lung cancer panel covers 11 genes with direct therapeutic implications for 20 targeted drugs, including those recommended in the latest NCCN guidelines. The panel detects all classes of genomic alterations including SNV, CNV, InDels and Fusion using routine FFPE samples, tumor tissue, DNA or peripheral blood.
Advantages
Gene Panel
| GENE | COVERAGE |
|---|---|
| EGFR | EGFR Exon 18, 19, 20, 21 base substitutions and InDels |
| ALK | ALK Exon 22, 23, 25 base substitutions; Fusions |
| KRAS | Exon 2, 3 base substitutions |
| NRAS | Exon 2, 3 base substitutions |
| MET | Exon 14 skipping mutations |
| BRAF | Exon 11, 15 base substitutionss |
| ROS1 | Fusions |
| RET | Fusions |
| DDR2 | Exon 18 base substitutions |
| ERBB2 | Exon 20 Indels |
| PIK3CA | Exon 20 base substitutions |
SENTISTM Colectoral Cancer (CRC) Panel
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions.
Colorectal cancer is the second leading cause of cancer-related mortality in the United States. BGI uses target region capture and NGS to examine 7 genes implicated in CRC targeted therapies, including those recommended in the latest NCCN guidelines.
Advantages
Gene Panel
| GENE | TYPE OF MUTATION | HOTSPOT MUTATIONS |
|---|---|---|
| KRAS | SNV | G12(C,R,S,A,D,V); G13(C,R,S,A,D,V); Q61(K,P,L,R,H); K117N; A146(P,T,V) |
| NRAS | SNV | G12(C,R,S,A,D,V); G13(C,R,S,A,D,V); Q61(K,P,L,R,H); A146(P,T,V) |
| BRAF | SNV | V600E, V600G, V600A |
| PIK3CA | SNV | E542K, E545(K,Q,A,G,V), Q546(E,K,L,P,R), D549N, H1047(L,R) |
| PTEN | SNV | R159S, R223*, Copy Number Loss |
| EGFR | SNV, CNV | S492R, Copy Number Gain |
| NOTCH1 | SNV, CNV | Copy Number Gain |
SENTISTM Targeted Drug Therapy Panel
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported.
BGI’s Targeted Drug Therapy Panel examines all exons and selected introns of 206 genes with direct therapeutic implications for 95 targeted therapies from a variety of sample input including fresh tissue, biopsy, FFPE, DNA and peripheral blood.
Advantages
SENTISTM Cancer+ Discovery Panel
BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions. Both tissue samples and liquid biopsy samples are supported (except for the Sentis Colorectal Cancer Panel for which a liquid biopsy version is still being developed).
BGI’s Cancer+ Discovery Panel is designed to identify all classes of actionable genomic alterations, including SNP, CNV, InDels and Fusions, across a total of 508 cancer-related genes. Results are supported by in depth mutation analysis and pharmacogenomics information relating to 102 cancer therapeutics approved by the FDA or currently undergoing clinical trials.